NCT05100641View on ClinicalTrials.gov

AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

672

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2029

Conditions
Primary Glioblastoma
Interventions
BIOLOGICAL

AV-GBM-1

Therapeutic autologous dendritic cell vaccine

BIOLOGICAL

Autologous monocytes

Autologous monocyte control

Sponsors
All Listed Sponsors
lead

Aivita Biomedical, Inc.

INDUSTRY